<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">Hyperglycaemia</z:e> frequently occurs in the <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e>, in patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, as well as those who were previously <z:chebi fb="105" ids="17234">glucose</z:chebi>-tolerant </plain></SENT>
<SENT sid="1" pm="."><plain>The terminology 'stress <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>' reflects the pathogenesis of the latter group, which may comprise up to 40% of <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>For comparable <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations during <z:hpo ids='HP_0011009'>acute</z:hpo> illness outcomes in stress <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> appear to be worse than those in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>While several studies have evaluated the optimum glycaemic range in the <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e>, their interpretation in relation to clinical recommendations is somewhat limited, at least in part because patients with stress <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and known <z:mp ids='MP_0002055'>diabetes</z:mp> were grouped together, and the optimum glycaemic range was regarded as static, rather than dynamic, phenomenon </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, there is increasing evidence that <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and glycaemic variability influence outcomes in the <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> adversely </plain></SENT>
<SENT sid="5" pm="."><plain>These three categories of disordered <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism can be referred to as dysglycaemia </plain></SENT>
<SENT sid="6" pm="."><plain>While stress <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is most frequently managed by administration of short-acting insulin, guided by simple algorithms, this does not treat <z:hpo ids='HP_0000001'>all</z:hpo> dysglycaemic categories; rather the use of insulin increases the risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and may exacerbate variability </plain></SENT>
<SENT sid="7" pm="."><plain>The pathogenesis of stress <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is complex, but hyperglucagonaemia, relative insulin deficiency and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> appear to be important </plain></SENT>
<SENT sid="8" pm="."><plain>Accordingly, novel agents that have a pathophysiological rationale and treat <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, but do not cause <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and limit glycaemic variability, are appealing </plain></SENT>
<SENT sid="9" pm="."><plain>The potential use of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (or its <z:chebi fb="4" ids="48705">agonists</z:chebi>) and dipeptyl-peptidase-4 inhibitors is reviewed </plain></SENT>
</text></document>